Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing Huawe Medicine Technology Group Co., Ltd, a move aimed at leveraging synergies in research and development (R&D) and manufacturing resources. The collaboration seeks to reduce drug development costs and enhance product competitiveness in the high-end pharmaceutical market. Financial details of the agreement were not disclosed.
The partnership will focus on the joint development of drugs, medical aesthetics, foods for special medical purposes (FSMP), and other products, covering areas such as product development, regulatory filing, commercial manufacturing, and marketing. Menovo Pharma is expected to establish a new special formulation production line as part of the strategic cooperation, which will include production lines for non-cytotoxic tumor high activity (OEB4), glucocorticoid production, and generic drug high activity (OEB4). Additionally, Menovo Pharma will provide Huawe with price support for production line operations. – Flcube.com
